New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 26, 2013
19:02 EDTPIP, SIGACourt affirms ruling that SIGA breached contractual obligation with PharmAthene
PharmAthene (PIP) announced that the Delaware Supreme Court upheld the earlier ruling that SIGA (SIGA) breached its contractual obligation to negotiate in good faith. The Court has remanded the case to the Delaware Court of Chancery for further reconsideration of the damages award, consistent with its opinion. "We are pleased by this positive decision from the Delaware Supreme Court, which conclusively affirms SIGA's liability for their failure to negotiate the terms of a license agreement with us in good faith," said Eric I. Richman, President and CEO. "Further, the Court established new Delaware law making expectation damages available in these circumstances. This is a significant legal victory for our Company and an important decision with respect to Delaware law. We look forward to final resolution of the case in front of the Delaware Court of Chancery." In addition, the Supreme Court also upheld the Delaware Court of Chancery decision entitling PharmAthene to receive reimbursement for a portion of its legal fees and expert witness costs and remanded to the Court of Chancery for further reconsideration of the amount of those fees and costs consistent with its opinion.
News For PIP;SIGA From The Last 14 Days
Check below for free stories on PIP;SIGA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
19:47 EDTSIGASIGA Technologies receives bankruptcy court approval for first-day motions
Subscribe for More Information
September 16, 2014
09:25 EDTPIP, SIGAOn The Fly: Pre-market Movers
Subscribe for More Information
06:51 EDTSIGASIGA Technologies files petition for relief to supply Tecovirimat
Subscribe for More Information
September 11, 2014
07:25 EDTPIPAegis to hold a conference
Subscribe for More Information
September 10, 2014
09:07 EDTPIPPharmAthene awarded $28.1M contract by NIAID
Subscribe for More Information
September 9, 2014
09:08 EDTPIPPharmAthene presented non-clinical animal data on SparVax anthrax vaccine
PharmAthene announced that recent non-clinical animal data from its SparVax anthrax vaccine program were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, or ICAAC, in Washington, DC. In a poster presentation Dr. Sherry Crowe, Director, Immunology for PharmAthene, presented an overview of non clinical animal studies of SparVax showing, among other things, that it can induce dose-dependent protective immunity in the established rabbit model for inhalational anthrax, and was statistically non-inferior to the currently licensed anthrax vaccine, BioThrax, when comparing survival and toxin neutralization assay results from the nonclinical anthrax aerosol challenge model.
September 8, 2014
10:14 EDTPIPPharmAthene, Nanotherapeutics form alliance
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use